Tisagenlecleucel in Non-Hodgkin Lymphoma: The Restricted Mean Survival Time as a Tool for Estimating Progression-Free Life Expectancy Better than the Median

被引：6
|
作者：
Chiumente, Marco [1 ]
Mengato, Daniele [2 ]
Messori, Andrea [3 ]
机构：
[1] Italian Soc Clin Pharm & Therapeut, Sci Direct, Milan, Italy
[2] Bolzano Cent Hosp, Dept Hosp Pharm, Bolzano, Italy
[3] Reg Hlth Serv, HTA Unit, Florence, Italy
来源：
ACTA HAEMATOLOGICA | 2020年 / 143卷 / 06期
关键词：
D O I：
10.1159/000505891
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：598 / 599
页数：2
相关论文
共 50 条
  • [21] Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma
    Epperla, Narendranath
    Ahn, Kwang Woo
    Ahmed, Sairah
    Jagasia, Madan
    DiGilio, Alyssa
    Devine, Steven M.
    Jaglowski, Samantha
    Kennedy, Vanessa
    Rezvani, Andrew R.
    Smith, Sonali M.
    Sureda, Anna
    Fenske, Timothy S.
    Kharfan-Dabaja, Mohamed A.
    Armand, Phillipe
    Hamadani, Mehdi
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [22] Expression of transmembrane 4 superfamily member, CD9, is related to improved progression-free survival in patients with diffuse non-Hodgkin's lymphoma
    Yau, JC
    Dabbagh, LK
    Formenti, KS
    Coupland, RW
    Burns, BF
    Shaw, AR
    ONCOLOGY REPORTS, 1998, 5 (06) : 1507 - 1511
  • [23] BENDABEAM PLUS AUTOLOGOUS STEM CELL TRANSPLANT PRODUCE A 3-YEAR PROGRESSION-FREE SURVIVAL RATE OF 75% IN HEAVILY PRE-TREATED HODGKIN AND NON-HODGKIN LYMPHOMA
    Visani, G.
    Stefani, P. M.
    Capria, S.
    Malerba, L.
    Galieni, P.
    Gaudio, F.
    Specchia, G.
    Meloni, G.
    Gherlinzoni, F.
    Giardini, C.
    Gobbi, M.
    Santoro, A.
    Ferrara, F.
    Rocchi, M.
    Ocio, E. M.
    Caballero, M. D.
    Loscocco, F.
    Isidori, A.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S171 - S171
  • [24] Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine131-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma
    Olney, Harold J.
    Freeman, Marni A.
    Stewart, Douglas A.
    Mangel, Joy E.
    White, Darrell J.
    Elia-Pacitti, Julia O.
    LEUKEMIA & LYMPHOMA, 2014, 55 (12) : 2754 - 2760
  • [25] Absolute lymphocyte count and CD4 count predict a superior progression-free survival in non-Hodgkin lymphoma patients treated with rituximab and interleukin-12.
    Joao, C
    Porrata, LF
    Witzig, T
    Kurtin, P
    Micallef, L
    Markovic, SN
    Erlichman, C
    Novak, A
    Ansell, SM
    BLOOD, 2005, 106 (11) : 430A - 431A
  • [26] Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival
    Shea, Thomas C.
    Beaven, Anne W.
    Moore, Dominic T.
    Serody, Jonathan S.
    Gabriel, Don A.
    Chao, Nelson
    Gockerman, Jon P.
    Garcia, Reynaldo A.
    Rizzieri, David A.
    LEUKEMIA & LYMPHOMA, 2009, 50 (05) : 741 - 748
  • [27] Potential Surrogate Endpoints for Progression-Free Survival (PFS) and Overall Survival (OS) in Non-Hodgkin Lymphoma: A Literature-Based Meta-analysis of Phase II and Phase III Studies
    Zhu, Rui
    Lu, Dan
    Chu, Wayne
    Chai, Akiko
    Green, Michelle
    Zhang, Nancy
    Jin, Jin Yan
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S78 - S78
  • [28] Inferior progression-free survival after autotransplant for relapsed or refractory aggressive non-hodgkin's lymphoma in patients > 60 versus < 60 years of age.
    Kuruvilla, John
    Gupta, Vikas
    Zaretsky, Yael
    Zadeh, Sahar
    Nagy, Tracy
    Keating, Armand
    Crump, Michael
    BLOOD, 2006, 108 (11) : 874A - 874A
  • [29] Complete Response (CR) to Induction Therapy in Patients (pts) with Myc plus and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS).
    Cohen, Jonathon B.
    Geyer, Susan
    Lozanski, Gerard
    Zhao, Weiqiang
    Heerema, Nyla A.
    Jones, Jeffrey A.
    Porcu, Pierluigi
    Christian, Beth
    Baiocchi, Robert A.
    Maddocks, Kami
    Flynn, Joseph M.
    Devine, Steven M.
    Blum, Kristie A.
    BLOOD, 2012, 120 (21)
  • [30] Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma
    Visani, Giuseppe
    Stefani, Pietro Maria
    Capria, Saveria
    Malerba, Lara
    Galieni, Piero
    Gaudio, Francesco
    Specchia, Giorgina
    Meloni, Giovanna
    Gherlinzoni, Filippo
    Giardini, Claudio
    Falcioni, Sadia
    Gonella, Roberta
    Cuberli, Francesca
    Gobbi, Marco
    Sarina, Barbara
    Santoro, Armando
    Ferrara, Felicetto
    Rocchi, Marco
    Ocio, Enrique M.
    Caballero, Maria Dolores
    Picardi, Paola
    Ricciardi, Teresa
    Loscocco, Federica
    Isidori, Alessandro
    BLOOD, 2013, 122 (21)
12345